Table 5 Clinical characteristics of thyroid dysfunction associated with PD-1 monoclonal antibody therapy in primary liver cancer
Clinical thyroid dysfunction (n = 71) | Subclinical thyroid dysfunction (n = 42) | P | t/ x2/Z | |
|---|---|---|---|---|
Gender (n, %) | 0.854 | 0.034 | ||
Male | 53(73.1) | 32(85.0) | ||
Female | 18(26.9) | 10(15.0) | ||
Age(years,x ± s) | 57.6 ± 11.0 | 60.1 ± 9.6 | 0.219 | 1.235 |
BMI | 24.5 ± 3.7 | 22.8 ± 3.1 | 0.032 | 2.18 |
Diabetes | 0.144 | 2.132 | ||
Yes | 8(11.3) | 9(21.4) | ||
No | 63(88.7) | 33(78.6) | ||
Evaluation time [weeks,M(Q1,Q3)] | 10.0(3.0, 25.5) | 10.0(5.7, 21.0) | 0.503 | 0.669 |
Hepatocellular carcinoma (n,%) | 0.719 | 0.546 | ||
Yes | 65(92.9) | 40(91.5) | ||
No | 6(7.1) | 2(6.1) | ||
Staging of BCLC system(n,%) | 0.4480 | 0.499 | ||
B | 17(24.3) | 8(19.0) | ||
C | 53(75.7) | 35(81.0) | ||
HBV or HCV(n,%) | 63(88.7) | 38(90.5) | 1.000 | 0.000 |
Cirrhosis (n,%) | 54(80.5) | 38(87.8) | 0.098 | 2.736 |
Decompensation stage (n,%) | 30(55.6) | 20(52.6) | 0.782 | 0.077 |
Yes | 24(44.4) | 18(47.4) | ||
No | ||||
Previous or combined treatment (n,%) | 7(9.9) | 9(21.4) | 0.088 | 2.906 |
Surgical resection | 51(71.8) | 34(81.0) | 0.278 | 1.178 |
TAE or TACE | 33(46.5) | 22(52.4) | 0.544 | 0.368 |
Tumor ablation | 49(69.0) | 28(66.7) | 0.796 | 0.067 |
Targeted agent | 4(5.6) | 2(4.8) | 1.000 | 0.000 |
Systemic chemotherapy | 10(14.1) | 4(9.5) | 0.678 | 0.173 |
Radiotherapy | 9(12.7) | 4(9.5) | 0.840 | 0.041 |
Name of PD-1 monoclonal antibody (n,%) | 0.254 | 1.303 | ||
Sintilimab | 40(56.3) | 19(45.2) | ||
Camrelizumab | 31(44.4) | 23(54.8) | ||
Thyroid antibody (n,%) | 0.306 | 1.050 | ||
Positive | 2(11.1) | 5(31.3) | ||
Negative | 16(88.9) | 11(68.8) |